Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in <scp>J</scp>apan

Seo, Kazunori; Koga, Ichiro; Kitazawa, Takatoshi; Ota, Yasuo

doi:10.1111/crj.12129

Cited by 18 publications

(28 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment was chosen by the physician in accordance with the patient’s medical condition. No significant difference was found between the peramivir (30.9 hours) and oseltamivir (34.7 hours) groups in terms of the median time to defervescence 50. Peramivir appeared to be as efficacious as oseltamivir.…”

Section: Resultsmentioning

confidence: 73%

Safety and efficacy of peramivir for influenza treatment

Hata¹,

Akashi-Ueda²,

Takamatsu³

et al. 2014

DDDT

View full text Add to dashboard Cite

ObjectiveThis report presents a review of the efficacy and safety of peramivir, a neuraminidase inhibitor that was granted Emergency Use Authorization by the US Food and Drug Administration (FDA) from October 23, 2009 to June 23, 2010 during the 2009 H1N1 pandemic.MethodsLiterature was accessed via PubMed (January 2000–April 2014) using several search terms: peramivir; BCX-1812; RWJ 270201; H1N1, influenza; antivirals; and neuraminidase inhibitors. The peramivir manufacturers, Shionogi and Co Ltd and BioCryst Pharmaceuticals, were contacted to obtain unpublished data and information presented at recent scientific meetings. Information was obtained from the Centers for Disease Control and Prevention (CDC) and from US FDA websites. English-language and Japanese-language reports in the literature were reviewed and selected based on relevance, along with information from the CDC, US FDA, and the drug manufacturers.ResultsWe obtained eleven clinical trial reports of intravenous peramivir, two of which described comparisons with oseltamivir. Seven of nine other recently reported published studies was a dose–response study. Clinical reports of critically ill patients and pediatric patients infected with pandemic H1N1 described that early treatment significantly decreased mortality. Peramivir administered at 300 mg once daily in adult patients with influenza significantly reduces the time to alleviation of symptoms or fever compared to placebo. It is likely to be as effective as other neuraminidase inhibitors.ConclusionAlthough peramivir shows efficacy for the treatment of seasonal and pH1N1 influenza, it has not received US FDA approval. Peramivir is used safely and efficiently in hospitalized adult and pediatric patients with suspected or laboratory-confirmed influenza. Peramivir might be a beneficial alternative antiviral treatment for many patients, including those unable to receive inhaled or oral neuraminidase inhibitors, or those requiring nonintravenous drug delivery.

show abstract

Section: Resultsmentioning

confidence: 73%

Safety and efficacy of peramivir for influenza treatment

Hata¹,

Akashi-Ueda²,

Takamatsu³

et al. 2014

DDDT

View full text Add to dashboard Cite

show abstract

“…Additional clinical trials, including open-label randomized trials as well as retrospective observational studies, are provided in Table 4 9,53–55,60…”

Section: Clinical Efficacy and Comparative Trials Of Peramivirmentioning

confidence: 99%

“…Additional studies have demonstrated the clinical effects of peramivir in adult patients 53,54. An open-label, randomized trial of hospitalized patients of ≥6 years of age was conducted by Ison et al54 to determine viral titer decline between two peramivir regimens.…”

Section: Clinical Efficacy and Comparative Trials Of Peramivirmentioning

confidence: 99%

Peramivir injection in the treatment of acute influenza: a review of the literature

Wester¹,

Shetty

2016

IDR

View full text Add to dashboard Cite

Influenza virus infection is a major cause of morbidity and mortality in children and adults globally. Seasonal epidemics are common due to the rapid virus evolution, whereas the frequent emergence of antigenic variants can result in pandemics and sporadic/endemic avian influenza virus infections. Although annual vaccination is the mainstay for influenza prevention and control, the use of antiviral agents must be considered for treatment and prophylaxis against influenza. Currently available antiviral drugs include neuraminidase inhibitors (NAIs), adamantanes, and a novel polymerase inhibitor (favipiravir). Peramivir is a recently US Food and Drug Administration-approved NAI for the treatment of acute uncomplicated influenza in adults. The chemical structure of peramivir allows it to bind to the influenza neuraminidase with much higher affinity than oseltamivir. Peramivir is effective against a variety of influenza A and B subtypes and has a lower half-maximal inhibitory concentration compared to other NAIs in in vitro studies. Peramivir can be administered intravenously, a route that is favorable for hospitalized, critically ill patients with influenza. The long half-life of peramivir allows for once-daily dosing. The drug is eliminated primarily by the kidneys, warranting dose adjustments in patients with renal dysfunction. Studies have assessed the clinical efficacy of peramivir for treatment of pandemic influenza A (H1N1). Although anecdotal evidence supports the use of peramivir in pediatric patients, pregnant women, and hospitalized patients with severe influenza receiving continuous renal replacement therapy and extracorporeal membrane oxygenation, well-designed, controlled clinical trials should be conducted in order to assess its clinical efficacy in these patient populations.

show abstract

“…Different NAI formulations have been developed to provide more treatment options for management of influenza. Peramivir, the first antiviral agent to be approved for intravenous administration in Japan and South Korea in 2010 and also approved in the USA in 2014, is intended to provide rapid control of progressive influenza in patients with serious complications [2]. A single administration of peramivir once daily was able to achieve treatment by stable binding with NA with the N9 subtype in a mouse model [3].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers

Zhang

Wang

et al. 2016

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan

Abstract: The clinical efficacy of peramivir is non-inferior to that of oseltamivir, although peramivir tended to be used in patients with serious complications. Intravenous administration of peramivir may be useful for patients with serious complications, such as consciousness disturbances.

Cited by 18 publications

References 10 publications

Safety and efficacy of peramivir for influenza treatment

Safety and efficacy of peramivir for influenza treatment

Peramivir injection in the treatment of acute influenza: a review of the literature

Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers

Contact Info

Product

Resources

About